Epidemiology, biology and therapy of Merkel cell carcinoma: conclusions from the EU project IMMOMEC

Juergen C. Becker*, Andreas Stang, Axel zur Hausen, Nicole Fischer, James A. DeCaprio, Richard W. Tothill, Rikke Lyngaa, Ulla Kring Hansen, Cathrin Ritter, Paul Nghiem, Christopher K. Bichakjian, Selma Ugurel, David Schrama

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

45 Citations (Web of Science)

Abstract

Merkel cell carcinoma (MCC) is a highly aggressive, often lethal neuroendocrine cancer. Its carcinogenesis may be either caused by the clonal integration of the Merkel cell polyomavirus into the host genome or by UV-induced mutations. Notably, virally-encoded oncoproteins and UV-induced mutations affect comparable signaling pathways such as RB restriction of cell cycle progression or p53 inactivation. Despite its low incidence, MCC recently received much attention based on its exquisite immunogenicity and the resulting major success of immune modulating therapies. Here, we summarize current knowledge on epidemiology, biology and therapy of MCC as conclusion of the project 'Immune Modulating strategies for treatment of Merkel Cell Carcinoma', which was funded over a 5-year period by the European Commission to investigate innovative immunotherapies for MCC.
Original languageEnglish
Pages (from-to)341-351
Number of pages11
JournalCancer Immunology Immunotherapy
Volume67
Issue number3
DOIs
Publication statusPublished - 1 Mar 2018

Keywords

  • Merkel cell carcinoma
  • Epidemiology
  • Cell of origin
  • Merkel cell polyomavirus
  • Immunotherapy
  • IMMOMEC
  • SMALL T-ANTIGEN
  • DOWN-REGULATION
  • POLYOMAVIRUS
  • EXPRESSION
  • RECURRENCE
  • GROWTH
  • PROLIFERATION
  • INHIBITION
  • PREVALENT
  • SURVIVAL

Cite this